Clene Financials

CLNN Stock  USD 4.46  0.10  2.19%   
Based on the measurements of operating efficiency obtained from Clene's historical financial statements, Clene Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Clene's Net Debt is very stable compared to the past year. As of the 18th of March 2025, Cash is likely to grow to about 26.5 M, while Other Current Liabilities is likely to drop about 4.1 M. Key indicators impacting Clene's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.681.76
Sufficiently Down
Pretty Stable
Investors should never underestimate Clene's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Clene's cash flow, debt, and profitability to make informed and accurate decisions about investing in Clene Inc.

Net Income

(42.33 Million)

  
Understanding current and past Clene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Clene's financial statements are interrelated, with each one affecting the others. For example, an increase in Clene's assets may result in an increase in income on the income statement.

Clene Stock Summary

Clene competes with MediciNova, Molecular Partners, Champions Oncology, Century Therapeutics, and Kezar Life. Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people.
Specialization
Consumer Defensive, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS1856341029
CUSIP185634102 185634201 G8959N106 G8959N130
LocationUtah; U.S.A
Business Address6550 South Millrock
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteclene.com
Phone801 676 9695
CurrencyUSD - US Dollar

Clene Key Financial Ratios

Clene Key Balance Sheet Accounts

202020212022202320242025 (projected)
Other Current Liab9.5M3.1M3.3M3.7M4.3M4.1M
Net Tangible Assets(67.8M)341K12.6M3.2M3.7M3.9M
Retained Earnings(153.6M)(163.3M)(193.2M)(242.7M)(218.5M)(229.4M)
Accounts Payable1.1M1.9M3.0M1.5M1.7M1.8M
Total Current Assets63.0M54.6M29.2M38.9M44.7M38.9M
Total Assets68.2M63.1M44.5M52.3M60.2M53.5M
Net Debt(55.0M)(26.2M)13.5M3.3M3.8M4.0M
Cash59.3M50.3M18.3M28.8M25.9M26.5M
Long Term Debt1.9M14.5M19.3M7.2M8.2M9.6M
Net Receivables2.2M1.6M189K1.3M1.2M946.1K
Inventory191K41K43K37K33.3K54.4K
Other Current Assets1.4M2.6M5.6M2.5M2.8M2.7M
Total Liab67.9M50.5M41.3M39.0M35.1M45.0M
Net Invested Capital2.3M31.7M28.9M40.0M46.1M48.4M
Net Working Capital51.3M48.6M15.3M13.5M12.2M21.4M
Short Term Debt768K986K7.5M20.1M23.1M24.3M

Clene Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense950K870K3.3M4.6M5.2M5.5M
Ebit(17.9M)(9.3M)(26.6M)(44.9M)(40.5M)(38.4M)
Net Interest Income(950K)(4.1M)(4.1M)(4.6M)(4.1M)(4.3M)
Total Revenue206K723K473K654K752.1K452.3K
Gross Profit141K434K447K533K613.0K643.6K
Operating Income(17.0M)(45.3M)(45.3M)(40.5M)(36.5M)(38.3M)
Research Development15.2M28.4M31.9M26.7M30.7M24.6M
Ebitda(16.9M)(8.2M)(25.2M)(43.2M)(38.9M)(37.0M)
Cost Of Revenue65K289K26K121K108.9K103.5K
Income Before Tax(18.9M)(10.2M)(29.9M)(49.5M)(44.6M)(42.3M)
Net Income(19.3M)(9.7M)(15.3M)(49.5M)(44.6M)(42.3M)
Income Tax Expense406K(428K)(14.6M)1.5M1.4M1.5M

Clene Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(163K)150K(2K)6K6.9K7.2K
Change In Cash50.5M(8.9M)(32.0M)10.5M9.4M9.9M
Net Borrowings(2.6M)6.6M19.5M5.6M6.5M7.3M
Depreciation963K955K1.0M1.7M2.0M1.1M
Capital Expenditures387K1.3M5.2M330K379.5K360.5K
Net Income(19.3M)(9.7M)(29.9M)(49.5M)(44.6M)(42.3M)
End Period Cash Flow59.3M50.3M18.4M28.9M33.2M33.5M
Change To Netincome953K2.6M10.7M8.3M9.6M5.5M
Investments(387K)(1.3M)(5.0M)7.0M8.0M8.4M
Free Cash Flow(19.3M)(36.0M)(44.2M)(30.5M)(27.5M)(28.8M)
Other Non Cash Items(13.2M)(37.6M)(17.1M)8.7M10.0M10.5M

Clene Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Clene's current stock value. Our valuation model uses many indicators to compare Clene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clene competition to find correlations between indicators driving Clene's intrinsic value. More Info.
Clene Inc is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Clene's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Clene's earnings, one of the primary drivers of an investment's value.

Clene Inc Systematic Risk

Clene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Clene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Clene Inc correlated with the market. If Beta is less than 0 Clene generally moves in the opposite direction as compared to the market. If Clene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Clene Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Clene is generally in the same direction as the market. If Beta > 1 Clene moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Clene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Clene's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Clene growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.005877)

At this time, Clene's Price Earnings To Growth Ratio is very stable compared to the past year.

Clene March 18, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Clene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Clene Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Clene Inc based on widely used predictive technical indicators. In general, we focus on analyzing Clene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Clene's daily price indicators and compare them against related drivers.
When determining whether Clene Inc is a strong investment it is important to analyze Clene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clene's future performance. For an informed investment choice regarding Clene Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clene Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.614
Earnings Share
(5.29)
Revenue Per Share
0.065
Quarterly Revenue Growth
(0.19)
Return On Assets
(0.47)
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.